Study identification

PURI

https://redirect.ema.europa.eu/resource/104350

EU PAS number

EUPAS104349

Study ID

104350

Official title and acronym

Utilization of antidementia treatments: a large multinational-network population-based study.

DARWIN EU® study

No

Study countries

Netherlands
United Kingdom

Study description

We aim to characterize and analyse the use of antidementia drugs in three different countries, through a multinational network cohort study that will gather information from real-world health care databases: Sistema d’Informació per al Desenvolupament de la Atenció Primària (SIDIAP), Health Informatic Center (HIC), Clinical Practice Research Datalink (CPRD) and the Integrated Primary Care Information (IPCI), standardized to the Common Data Model OMOP. Inclusion criteria: we will include individuals with at least 40 years or older with dementia, registered for at least 1 year before cohort entry and with at least 1 prescription of rivastigmine, galantamine, donepezil or memantine during the study period. Outcomes: demographics, comorbidities, prescriber-type, prescribing pattern and proportion of ‘prescription cascade’ drugs (prescriptions generated to alleviate adverse events). Statistics: Yearly age-sex incidence rates (IR) and Kaplan Meier curves to assess the duration and drug discontinuation.

Study status

Planned
Research institutions and networks

Institutions

IPCI The Netherlands, HIC Scotland (UK)

Contact details

Carlen Reyes

Primary lead investigator
Study timelines

Date when funding contract was signed

Planned:

Study start date

Planned:

Date of final study report

Planned:
Sources of funding
Other

More details on funding

IDIAPJGol, University of Oxford
Regulatory

Was the study required by a regulatory body?

No

Is the study required by a Risk Management Plan (RMP)?

Not applicable